Amanote Research
Register
Sign In
Trial of SAGE-217 in Patients With Major Depressive Disorder
New England Journal of Medicine
- United States
doi 10.1056/nejmc1913170
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Date
November 28, 2019
Authors
Unknown
Publisher
Massachusetts Medical Society
Related search
Dental Patients With Major Depressive Disorder
Current Oral Health Reports
Pmh76 - Patient Reported Measures of Depressive Symptoms and Fatigue in a Phase 2, Randomized, Placebo-Controlled Trial of the Gabaa Receptor Positive Allosteric Modulator Sage-217 in Major Depressive Disorder
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Dream Contents in Patients With Major Depressive Disorder
Canadian Journal of Psychiatry
Psychiatry
Mental Health
Hypothyroidism in Patients With Asthma and Major Depressive Disorder
The Primary Care Companion to The Journal of Clinical Psychiatry
Acetyl-L-Carnitine Deficiency in Patients With Major Depressive Disorder
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Impaired Social Decision Making in Patients With Major Depressive Disorder
BMC Psychiatry
Psychiatry
Mental Health
Duloxetine-Induced Liver Injury in Patients With Major Depressive Disorder
Psychiatry Investigation
Psychiatry
Mental Health
Biological Psychiatry
Pmh77 - Assessment of Health-Related Quality of Life by the Sf36v2 in a Phase 2, Randomized, Placebo-Controlled Trial of the Gabaa Receptor Positive Allosteric Modulator Sage-217 in Major Depressive Disorder
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Impact of Aerobic Exercise on Muscle Mass in Patients With Major Depressive Disorder: A Randomized Controlled Trial
Neuropsychiatric Disease and Treatment
